Declaration of competing financial interests

From the following article

Bench to bedside: BRCA: From therapeutic target to therapeutic shield

Neil P Shah

Nature Medicine 14, 495 - 496 (2008)

doi:10.1038/nm0508-495

BACK TO ARTICLE

Declaration: N.P.S. has served as a consultant for Bristol-Myers Squibb (manufacturer of cisplantin) and Novartis (manufacturer of imatinib).

BACK TO ARTICLE